Amryt Pharma plc (AMYT)
Chart Events
Performance Outlook
| Previous Close | 11.33 |
| Open | 11.18 |
| Bid | 11.18 x 1100 |
| Ask | 14.15 x 900 |
| Day's Range | 11.12 - 11.44 |
| 52 Week Range | 10.06 - 15.44 |
| Volume | 32,017 |
| Avg. Volume | 79,766 |
| Market Cap | 401.105M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Insider Monkey
10 Best Stocks to Buy According to Highbridge Capital
In this article we will take a look at the 10 best stocks to buy according to billionaire Glenn Russell Dubin’s Highbridge Capital Management. You can skip our detailed analysis of Dubin’s history, investment philosophy, and hedge fund performance, and go directly to the 5 Best Stocks to Buy According to Billionaire Glenn Russell Dubin’s […]
- Zacks
Amryt (AMYT) NDA for Skin Disorder Drug Gets Priority Review
Amryt (AMYT) is seeking approval for Oleogel-S10 as a potential treatment for patients with rare and distressing genetic skin disorder, epidermolysis bullosa.
- Benzinga
Amryt Pharma's Oleogel-S10 Application Gets FDA Priority Review Tag for Skin Blistering Disorder
The FDA has granted priority review status to Amryt Pharma's (NASDAQ: AMYT) marketing application seeking approval for Oleogel-S10 to treat Epidermolysis Bullosa (EB). Oleogel-S10 is a potential treatment for the cutaneous manifestations of Junctional and Dystrophic EB, a rare genetic skin disorder characterized by blistering lesions on the skin and mucous membranes. In general, the FDA's Priority Review designation accelerates the review time from ten months to a goal of six months from the dat
